Adverse Reactions from Anti-Tuberculosis Drugs in Patients with Pulmonary Tuberculosis

Main Article Content

Tashpulatova Fatima Kudratovna


This article focuses on the adverse reactions that patients with pulmonary tuberculosis may experience from anti-tuberculosis drugs. The study aims to identify the common adverse reactions, their severity, and the risk factors associated with their occurrence. By analyzing previous relevant studies and examining data on patients with pulmonary tuberculosis, the article highlights the importance of monitoring patients for adverse drug reactions and adjusting their treatment plan accordingly. The results indicate that the occurrence of adverse reactions is a common problem in patients with pulmonary tuberculosis, which can lead to treatment discontinuation and poor treatment outcomes. Therefore, healthcare providers need to be aware of these adverse reactions and implement proactive measures to minimize their impact on patients. Overall, this article provides valuable insights for clinicians who prescribe anti-tuberculosis drugs and aims to improve patient care and treatment outcomes.

Article Details

How to Cite
Tashpulatova Fatima Kudratovna. (2023). Adverse Reactions from Anti-Tuberculosis Drugs in Patients with Pulmonary Tuberculosis. Journal of Coastal Life Medicine, 11(1), 1298–1301. Retrieved from


World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization; 2021.

Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195.

Lee CH, Lee MC, Chang CH, et al. Adverse events of anti-tuberculosis drugs in hospitalized patients: a 10-year retrospective study. Int J Tuberc Lung Dis. 2013;17(3):357-364.

Alffenaar JW, Akkerman OW, Alves TM, et al. Precision dosing of anti-tuberculosis medication: the way forward. Lancet Infect Dis. 2020;20(3):e74-e83.

Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192-202.

Abah, J. O., Omeje, E. U., Okwuzu, C. C., & Okoli, C. V. (2019). Profile of adverse drug reactions experienced by tuberculosis patients on therapy in a Nigerian tertiary hospital. Journal of Pharmacology and Pharmacotherapeutics, 10(3), 106–110.

Alqahtani, J. M., Asiri, Y. A., Alshehri, S. A., & Alghamdi, R. S. (2018). Adverse drug reactions to antituberculosis drugs in Saudi Arabian patients. Clinical and Experimental Pharmacology and Physiology, 45(5), 497–502.

Shafiee, S., Bahrani, F., Kiaee, F., Esmaeili, S., Ziabakhsh Tabary, S.& Shahriarirad, R. (2019). Frequency of adverse drug reactions to tuberculosis drugs in patients with pulmonary tuberculosis in Golestan Province, Iran. Turkish Journal of Medical Sciences, 49(2), 565-570.

World Health Organization. (2014). Treatment of Tuberculosis: Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care. Retrieved from

Wu, S., Zhang, Y., Sun, F., Chen, M., Zhou, L., Wang, N., & Zhan, S. (2016). Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. American journal of therapeutics, 23(2), e521-e530.

American Thoracic Society, Centers for Disease Control and Prevention, & Infectious Diseases Society of America. (2016). Treatment of drug-susceptible tuberculosis: Official ATS/CDC/IDSA clinical practice guidelines. Clin Infect Dis, 63(7), e147-e195. doi: 10.1093/cid/ciw376

Nahid, P., Dorman, S. E., Alipanah, N., et al. (2016). Executive summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis, 63(7), 853-867. doi: 10.1093/cid/ciw566

World Health Organization. (2019). WHO consolidated guidelines on tuberculosis: module 4: treatment—drug-resistant tuberculosis treatment. World Health Organization.

Sotgiu, G., Migliori, G. B., Centis, R., D'Ambrosio, L., Fernández-Vera, J. R., Spanevello, A., … & Blasi, F. (2016). Tuberculosis treatment and drug regimens. Cold Spring Harbor perspectives in medicine, 6(9), a022670.

Caminero, J. A. (2018). Management of drug-resistant tuberculosis. Drugs, 78(11), 1127-1153.

Singla, R., Gupta, R., & Sarin, R. (2011). Thirty years’ experience of treating tuberculosis in a referral institute. The Indian Journal of Chest Diseases & Allied Sciences, 53(4), 179-184